CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: October 26, 2015
Result type: Reports
Project Number: SF0453-000
Product Line: Reimbursement Review

Generic Name: Denosumab

Brand Name: Prolia

Manufacturer: Amgen Canada Inc.

Therapeutic Area: Osteoporosis

Indications: Osteoporosis, postmenopausal women

Submission Type: Request For Advice

Project Status: Complete

Date Recommendation Issued: May 20, 2016

Recommendation Type: Reimburse with clinical criteria and/or conditions